Overview
Dr. Schmader’s areas of research include herpes zoster, infections, and vaccines in older adults. He conducts translational, clinical trials and observational studies of zoster, influenza, and other infections funded by grants from the National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control (CDC), VA Office of Research and Development, and Industry sources. He has played a pivotal role in the development of zoster vaccines in older adults. Dr. Schmader also performs research in medications and older adults, focusing on pharmacoepidemiology, optimal drug use and reduction of adverse drug reactions.
He is the Director of the NIA-funded P30 Duke Pepper Older Americans Independence Center, Co-investigator of the NIAID funded Collaborative Influenza Vaccine Innovation Centers (CIVICS) and the CDC Clinical Immunization Safety Assessment (CISA) office at Duke. He serves on the Working Groups for the Herpes Zoster, Influenza, COVID-19, RSV and General Adult Immunization Guidelines for the US Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) and is the American Geriatrics Society liaison to the ACIP.
Current Appointments & Affiliations
Recent Publications
Polypharmacy and potentially inappropriate medication (PIM) use among older veterans with idiopathic pulmonary fibrosis (IPF) - a retrospective cohort study.
Journal Article BMC Pulm Med · April 21, 2025 BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a deadly respiratory disease of older patients. IPF therapies (antifibrotics) are efficacious in slowing disease progression, but they are critically underutilized. Potential barriers to antifibrotic use a ... Full text Link to item CiteCan Pharmacogenetics Be Used to Predict the Response to Fesoterodine Fumarate?
Journal Article Urogynecology (Phila) · February 14, 2025 IMPORTANCE: Pharmacogenetics could address the challenge of predicting an individual's response to anticholinergic medications for urgency urinary incontinence (UUI). OBJECTIVES: Our objectives were to evaluate whether the metabolizer status of cytochrome ... Full text Link to item CiteNeutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Journal Article Clin Infect Dis · February 5, 2025 For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard r ... Full text Link to item CiteRecent Grants
Duke/UNC ADAR Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029CISA 2023 Clinical Contributing Task 2
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028CISA 2023 Clinical Contributing Task 1
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028View All Grants